文献速递神经肿瘤

胶质母细胞瘤人群的拷贝数谱分析对临床试验设计的意义

Copy number profiling across glioblastoma populations has implications for clinical trial design.
PubMed 文献 · Neuro Oncol · 2018-01-01

本研究利用4个胶质母细胞瘤队列的分子数据,定义拷贝数亚型的分布在随机队列与存在选择偏倚的队列间的差异。结果显示,较小的选择性胶质母细胞瘤队列富集了与更好生存相关的拷贝数亚型,反映了患者选择偏倚。因此,临床试验入组时纳入分子谱分析(包括拷贝数)可能对平衡组间和推断至一般胶质母细胞瘤人群具有重要意义。

要点

  • 较小的选择性胶质母细胞瘤队列富集与更好生存相关的拷贝数亚型。
  • 临床试验入组时的患者选择偏倚可能影响分子亚型分布。
  • 作者认为临床试验入组时纳入分子谱分析(包括拷贝数)可能重要。

核心结论

  • 弥漫性胶质瘤患者的总体结局由初始肿瘤切除时的DNA结构预测。
  • 胶质母细胞瘤人群间的分子特征变化反映了临床试验中患者选择偏向更长生存的固有偏倚。
  • 作者认为临床试验入组时纳入分子谱分析(包括拷贝数)可能对平衡组间和推断至一般胶质母细胞瘤人群具有重要意义。

研究设计与样本

  • 研究建立了4个胶质母细胞瘤患者队列的拷贝数亚型频率。
  • 两个随机选择的队列包括癌症基因组图谱(TCGA)和德国胶质瘤网络(GGN)。
  • 两个更具选择性的队列包括针对老年新诊断胶质母细胞瘤患者的II期试验ARTE和专注于配对切除的原发/复发胶质母细胞瘤的多机构队列。
  • 配对的原发/复发队列还有外显子组数据可用,允许进行多维标度分析评估。

主要发现

  • 较小的选择性胶质母细胞瘤队列富集了与更好生存相关的拷贝数亚型,反映了选择足够好以进入临床试验或被认为足够好以在复发时接受切除的患者。
  • 将外显子组数据加入拷贝数数据提供了反映结局的额外数据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Copy number alterations form prognostic molecular subtypes of glioblastoma with clear differences in median overall survival. In this study, we leverage molecular data from several glioblastoma cohorts to define the distribution of copy number subtypes across random cohorts as well as cohorts with selection biases for patients with inherently better outcome. METHODS: Copy number subtype frequency was established for 4 glioblastoma patient cohorts. Two randomly selected cohorts include The Cancer Genome Atlas (TCGA) and the German Glioma Network (GGN). Two more selective cohorts include the phase II trial ARTE in elderly patients with newly diagnosed glioblastoma and a multi-institutional cohort focused on paired resected initial/recurrent glioblastoma. The paired initial/recurrent cohort also had exome data available, which allowed for evaluation of multidimensional scaling analysis. RESULTS: Smaller selective glioblastoma cohorts are enriched for copy number subtypes that are associated with better survival, reflecting the selection of patients who do well enough to enter a clinical trial or who are deemed well enough to undergo resection at recurrence. Adding exome data to copy number data provides additional data reflective of outcome. CONCLUSIONS: The overall outcome for diffuse glioma patients is predicted by DNA structure at initial tumor resection. Molecular signature shifts across glioblastoma populations reflect the inherent bias of patient selection toward longer survival in clinical trials. Therefore it may be important to include molecular profiling, including copy number, when enrolling patients for clinical trials in order to balance arms and extrapolate relevance to the general glioblastoma population.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Cimino PJ, McFerrin L, Wirsching HG, et al. Copy number profiling across glioblastoma populations has implications for clinical trial design. Neuro Oncol. 2018. PMID: 29982740. doi:10.1093/neuonc/noy108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。